MedImmune taps Israeli bi-specific antibody programme

By Flora Southey contact

- Last updated on GMT

GettyImages/knorre
GettyImages/knorre
MedImmune will make bi-specific and multi-specific antibody products developed from Compugen’s pipeline under an exclusive license agreement.

Bi and multi-specific antibodies are genetically engineered to bind to different target proteins, which can enable multiple mechanisms of action for treatment within a single molecule.

According to the deal, MedImmune – AstraZeneca’s biologics R&D arm – will be responsible for research, development and commercial activities for any products created.

Compugen will receive $10m upfront from MedImmune as well as development, regulatory and commercial milestone payments for the first product.

“We are eligible for $200m in milestones [for the first product developed under the license] and then of course royalties on product sales,” ​Compugen CSO Kirk Christoffersen told investors on Monday.

“Past that, this deal has always been envisioned to have multiple products, and each one of those products will have its own milestone and royalty scheme,” ​he said, adding that he was unable to disclose milestone triggers for future product payments.

Compugen CEO Anat Cohen-Dayag could not disclose the target of the license agreement, nor when MedImmune would come forth with further information regarding indications.

“We have licensed to them [MedImmune] all rights and uses, they have the rights to develop in any therapeutic that their interested in,” ​Christoffersen echoed.

Last month, we reported​ that Compugen had signed an agreement with Selexis’ to use its SUREtechnology mammalian cell line-based protein expression platform to help develop immune-oncology products.

Related news

Show more

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us

Products

View more

Webinars